The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

PRNewswire Bangalore Karnataka [India] January 15 Manipal Hospitals Sarjapur Road recently hosted an awareness session on ...

Spruce Point Capital Management issued a report entitled, “Pulling Back the Curtain on Procept,” that outlines why the firm believes and ...

Manipal Hospitals Sarjapur Road hosted a session on HoLEP for Benign Prostatic Hyperplasia. This innovative technique, led by ...

Spruce Point Capital Management, LLC ("Spruce Point" or "we" or "us"), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report ...

The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

Urology of Virginia is proud to announce the opening of our state-of-the-art Interventional Radiology Department, a milestone ...

Profound Medical's Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th ...

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical ...

Opella reaches study milestone for Cialis Paris1, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its ...